We are live on
!
Find out more
PFO
Pathstone Family Office Portfolio holdings
AUM
$13.1B
1-Year Est. Return
21.02%
This Fund
S&P 500
This Quarter
Est. Return
+0.72%
1 Year Est. Return
+21.02%
3 Year Est. Return
+39.27%
5 Year Est. Return
+59.55%
10 Year Est. Return
+237.03%
AUM
$768M
AUM Growth
-$80.1M
(-9.5%)
Cap. Flow
-$27.1M
Cap. Flow
% of AUM
-3.53%
Top 10 Holdings %
Top 10 Hldgs %
60.99%
Holding
740
New
85
Increased
91
Reduced
143
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$1.75M |
| 2 |
AMJ
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
|
+$1.16M |
| 3 |
Lyft
LYFT
|
+$989K |
| 4 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$721K |
| 5 |
Xylem
XYL
|
+$522K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royal Bank of Canada
RY
|
+$11.3M |
| 2 |
iShares Russell 1000 ETF
IWB
|
+$9.09M |
| 3 |
CarMax
KMX
|
+$5.75M |
| 4 |
iShares Core MSCI EAFE ETF
IEFA
|
+$2.77M |
| 5 |
Microsoft
MSFT
|
+$2.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 25.36% |
| 2 | Technology | 10.73% |
| 3 | Consumer Discretionary | 9.26% |
| 4 | Communication Services | 3.87% |
| 5 | Industrials | 3.37% |
Similar funds
CG
API
TA
SCH
PWAG
CS
IWP
MAM
Pathstone Family Office's Q3 2019 Portfolio in Review
As of Q3 2019, Pathstone Family Office held 740 positions worth $768M, down 9.5% from $848M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Pathstone Family Office withdrew a net $27.1M in Q3 2019, closing 103 positions and reducing 143 holdings. Its most notable exit was UroGen Pharma, an estimated $1.47M position sold in full.
By sector, the portfolio is most concentrated in Financials at 25% of assets, up from 25% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Pathstone Family Office opened a new position in Xylem worth $529K.
- Pathstone Family Office's largest Q3 2019 buy was Xylem: 6,643 shares worth $529K.
- Pathstone Family Office added most to Vanguard S&P 500 ETF in Q3 2019, an estimated $1.75M increase.
- Pathstone Family Office's biggest Q3 2019 reduction was Royal Bank of Canada, cutting an estimated $11.3M.
- Pathstone Family Office fully exited UroGen Pharma in Q3 2019, selling an estimated $1.47M.
- Pathstone Family Office's ten largest holdings make up 61% of its $768M portfolio in Q3 2019.
- Pathstone Family Office opened 85 new positions and closed 103 in Q3 2019.
- Pathstone Family Office's portfolio value fell 9.5% quarter-over-quarter to $768M.
Based on Pathstone Family Office's 13F filing for Q3 2019, filed 13 Nov 2019.